	US 11,679,142 B2
	B7-H1 fusion polypeptides for treating and preventing organ failure
Andreas Von Knethen, Nidderau (DE); Michael Parnham, Bad Soden/Ts. (DE); and Lisa Katharina Sha, Hattgenstein (DE)
Assigned to Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., Munich (DE)
Filed by Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., Munich (DE)
Filed on Mar. 18, 2020, as Appl. No. 16/822,240.
Application 16/822,240 is a continuation of application No. 15/753,541, granted, now 10,632,174, previously published as PCT/EP2016/069680, filed on Aug. 19, 2016.
Claims priority of application No. 15181800 (EP), filed on Aug. 20, 2015.
Prior Publication US 2020/0215159 A1, Jul. 9, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 47/68 (2017.01); A61P 37/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 9/00 (2006.01)

CPC A61K 38/1774 (2013.01) [A61K 39/395 (2013.01); A61K 45/06 (2013.01); A61K 47/6811 (2017.08); A61K 47/6835 (2017.08); A61P 9/00 (2018.01); A61P 37/00 (2018.01); C07K 2319/30 (2013.01)]

14 Claims

1. A method of at least one of treating or preventing organ failure in a subject suffering from sepsis, said method comprising (a) administering to said subject a therapeutically effective amount of a fusion polypeptide comprising at least (i) a first portion being an Fc portion of an immunoglobulin and (ii) a second portion comprising the extracellular portion of the human B7-H1 polypeptide or a variant thereof or (b) administering a therapeutically effective amount of a polynucleotide encoding said fusion polypeptide.